Oculis Holding AG

Listed Company
OCSCIK 0001953530NasdaqLarge AcceleratedPharmaceutical PreparationsV8CHFY ends Dec 31
Period
FY 2025
Revenue
Net Income
$-98.96M
Total Assets
$235.96M
Equity
Shares Out
Op. Cash Flow

Business

Oculis Holding AG develops and advances product candidates through research and development programs focused on proprietary technologies. It primarily offers development programs and product candidates protected by patents, trademarks, trade secrets and confidentiality agreements, and pursues patent filings and licensing where applicable. The company engages in material licenses, partnerships and collaborations to support development and potential commercialization of its candidates. Oculis seeks intellectual property protection and pursues filings in the United States and other countries, and relies on collaborations and licensing arrangements for broader development and distribution.

Summary from filing dated 2025-03-11

Financials

Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.

Revenue
Net income$-98.96M
Total assets$235.96M
Total liabilities$39.89M
Stockholders' equity
Operating cash flow

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro